Skip to main content

Table 1 Demographic and clinical characteristics of 342 women diagnosed with invasive breast cancer (stages I–III) by race, Emory University, 2007–2012

From: Detection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer

  

Race

Total

African-American

White

(N = 342)

(N = 174)

(N = 168)

Demographic characteristics

Age at diagnosis (years)

  Mean (SD)

55.25 (13.20)

55.71 (13.91)

54.78 (12.43)

BMI (kg/m2),n(%)

  < 25

126 (37.1)

40 (23.3)

86 (51.2)

  25 to < 30

85 (25.0)

43 (25.0)

42 (25.0)

  ≥ 30

129 (37.9)

89 (51.7)

40 (23.8)

Smoking status,n(%)

  Non-smoker

225 (67.0)

111 (64.5)

114 (69.5)

  Past smoker

87 (25.9)

44 (25.6)

43 (26.2)

  Current smoker

24 (7.1)

17 (9.9)

7 (4.3)

Age at menarche (years)

  Mean (SD)

12.68 (1.66)

12.59 (1.69)

12.77 (1.63)

Parity

  Nulliparous

44 (15.0)

19 (13.1)

25 (16.9)

  Parous (1+ live births)

249 (85.0)

126 (86.9)

123 (83.1)

History of breastfeedinga,n(%)

  No

75 (39.5)

38 (45.2)

37 (34.9)

  Yes

115 (60.5)

46 (54.8)

69 (65.1)

Menopausal status,n(%)

  Pre-/perimenopausal

117 (36.1)

59 (36.9)

58 (35.4)

  Postmenopausal

207 (63.9)

101 (63.1)

106 (64.6)

Age at menopauseb,n(%)

  < 45 years

83 (45.4)

46 (53.5)

37 (38.1)

  45 to < 50 years

35 (19.1)

17 (19.8)

18 (18.6)

  50 to < 55 years

50 (27.3)

17 (19.8)

33 (34.0)

  ≥ 55 years

15 (8.2)

6 (7.0)

9 (9.3)

History of hormone replacement therapy useb,n(%)

  No

120 (63.8)

66 (75.0)

54 (54.0)

  Yes

68 (36.2)

22 (25.0)

46 (46.0)

Family history of breast cancer among first-degree relatives,n(%)

  No

240 (73.6)

118 (74.2)

122 (73.1)

  Yes

86 (26.4)

41 (25.8)

45 (26.9)

Diabetes status,n(%)

  No

298 (87.1)

140 (80.5)

158 (94.0)

  Yes

44 (12.9)

34 (19.5)

10 (6.0)

Hypertension status,n(%)

  No

200 (58.5)

82 (47.1)

118 (70.2)

  Yes

142 (41.5)

92 (52.9)

50 (29.8)

High cholesterol status,n(%)

  No

286 (83.6)

141 (81.0)

145 (86.3)

  Yes

56 (16.4)

33 (19.0)

23 (13.7)

Clinical characteristics

ER status,n(%)

  Positive

267 (79.0)

120 (70.2)

147 (88.0)

  Negative

71 (21.0)

51 (29.8)

20 (12.0)

Stage,n(%)

  Stage I

163 (47.7)

76 (43.7)

87 (51.8)

  Stage II

135 (39.5)

75 (43.1)

60 (35.7)

  Stage III

44 (12.9)

23 (13.2)

21 (12.5)

Tumor grade,n(%)

  Well differentiated

75 (22.9)

30 (18.2)

45 (27.6)

  Moderately differentiated

150 (45.7)

68 (41.2)

82 (50.3)

  Poorly differentiated

103 (31.4)

67 (40.6)

36 (22.1)

Tumor size (cm),n(%)

  ≤ 0.5

7 (2.4)

2 (1.4)

5 (3.3)

  0.5 to < 1

43 (14.5)

20 (13.9)

23 (15.0)

  1 to < 5

222 (74.7)

102 (70.8)

120 (78.4)

  ≥ 5

25 (8.4)

20 (13.9)

5 (3.3)

Number of positive lymph nodes,n(%)

  0

204 (65.6)

101 (64.7)

103 (66.5)

   ≥ 1

107 (34.4)

55 (35.3)

52 (33.5)

Chemotherapy,n(%)

  No

172 (52.4)

70 (43.5)

102 (61.1)

  Yes

156 (47.6)

91 (56.5)

65 (38.9)

Radiation,n(%)

  No

235 (71.4)

105 (65.2)

130 (77.4)

  Yes

94 (28.6)

56 (34.8)

38 (22.6)

Hormone therapy,n(%)

  No

109 (31.9)

71 (40.8)

38 (22.6)

  Yes

233 (68.1)

103 (59.2)

130 (77.4)

  1. Abbreviations: BMI body mass index, SD standard deviation
  2. Note: Missing values were not included in the calculation of percentages
  3. aAmong parous women
  4. bAmong postmenopausal women only